Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

Inclusion criteria

* All patients must have histologically or cytologically documented small cell carcinoma of the bronchus * The extensive disease classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive stage patients are defined as those patients with extrathoracic metastases, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy or contralateral hilar adenopathy * Measurable or Non-measurable Disease * No prior chemotherapy or investigational therapy for SCLC * Radiation therapy must have been completed at least three weeks before initiation of protocol therapy * No major surgical procedure within 28 days prior to starting treatment and fully recovered * No minor surgical procedure (mediastinoscopy or core biopsy) within 7 days prior to starting treatment * ECOG performance status: 0-2 * No currently active second malignancy other than non-melanoma skin cancers * No CNS metastases; patients with a history of CNS metastases will NOT be eligible even if they have completed a course of CNS radiotherapy; all patients will have a screening brain CT or MRI to rule out occult CNS metastases * No recent history of CVA (within 6 months) * No serious or non-healing wound ulcer or bone fracture * Patients with a history of significant bleeding episodes (e.g., hemoptysis, bleeding diathesis, upper or lower GI bleeding) are not eligible; patients with trace blood in the sputum (blood tinged sputum) are eligible * No myocardial infarction or significant change in anginal pattern within one year or current congestive heart failure (NYHA Class 2 or higher) * Patients with a history of hypertension must be well controlled (\< 150/90) on a stable regimen of anti-hypertensive therapy * No HIV-positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with the protocol treatment; (patients with immune deficiency are at an increased risk of lethal infections when treated with marrow-suppressive therapy) * No chronic daily treatment with aspirin (\> 325 mg/day) or on non-steroidal antiinflammatory agents known to inhibit platelet function; no treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix), cilostazol (Pletal), or other antiplatelet agents * No clinically significant peripheral neuropathy (grade \>= 2) * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No treatment with therapeutic anticoagulation; prophylactic anticoagulation for central venous access devices is allowed provided requirements of INR \< 1.5 and PTT \< 1.2 x ULN are met; caution should be taken in treating patients with low dose heparin or low molecular weight heparin for DVT prophylaxis as there may be an increased bleeding risk with bevacizumab * No current and/or recent (within 1 month) use of a thrombolytic agent; low dose thrombolytic therapy for maintenance of central venous catheter is allowed * No clinically significant peripheral arterial disease * Non-pregnant and non-nursing; the effect of the combination of bevacizumab, cisplatin, and irinotecan on the fetus and infant is unknown * Granulocytes \>= 1,500/μl * Platelets \>= 100,000/μl * Serum Creatinine =\< ULN * Total Bilirubin \< 2.0 mg/dl * SGOT \< 2 x ULN * INR \< 1.5 * PTT \< 1.2 x ULN * Urine protein (dipstick) \< 1+